The DOI matches its Crossref record; 49 of the 51 references it cites were found in a registry or an index, and 2 are not checked yet.
The effect of Berberine on weight loss in order to prevent obesity: A systematic review
Open accessAbstract
This study provides a critical overview of experimental studies in vitro, in humans, and in animals that evaluated the efficacy of Berberine and its effect on management of obesity and the related metabolic consequences. As a result of this review, we summarized the effects of Berberine in different models and the related mechanism of actions. In preclinical models, Berberine demonstrates that it affects gut microbiota by reducing diversity of microbes starting at a dosage of 100 mg/kg/day. Moreover, in animal models, Berberine explicates an action on glucose through the inhibition of α-glycosidase at a dose of 200 mh/kg/day. Berberine is also known to be effective against differentiation of adipocytes through a decrease in LXRs, PPARs, and SREBPs expression at 150 mg/kg/day. Other mechanism ascribed to Berberine are related to its inhibition of hepatic gluconeogenesis through the Phospheoenolpyruvate carboxykinase (PEPCK), Glucose-6-phosphate (G6Pase) and AMP-activated protein kinase (AMPK). Furthermore, Berberine (associated to Red Yeast Rice) is effective in decreasing lipid levels in rats, which consequently lowers the change of weight gain at dosage of 40 mg/kg to 380 mg/kg/day. All the above preclinical data are confirmed in human studies where Berberine can modulate the diversity of gut microbes at the dose of 500 mg/day. In addition, Berberine is found to have a beneficial impact on gene regulation for the absorption of cholesterol at a daily dose of 300 mg in humans, an amelioration on glucose accumulation at 1.0 g daily dose was also observed. For all these reasons, this review gives an important good account of the impact of Berberine in obesity treatment and prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As we all know, dyslipidemia and inflammation are risk factors of micro- and macrovascular leisures, our meta-analysis suggest that berberine has potential benefits on diabetes with cardiovascular and chronic kidney disease, which has been reported in preclinical studies [81, 82].”
From The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
Finucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., Singh, G. M., Gutierrez, H. R., Lu, Y., Bahalim, A. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62037-5 · Cited by 4,050
Cani, P. D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., Geurts, L., Naslain, D., Neyrinck, A., Lambert, D. M., et al. (2009) · Gut · doi:10.1136/gut.2008.165886 · Cited by 2,518
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Efficacy of berberine in patients with type 2 diabetes mellitus
Yin, J., Xing, H., & Ye, J. (2008) · Metabolism · doi:10.1016/j.metabol.2008.01.013 · Cited by 801
Zhang, X., Zhao, Y., Xu, J., Xue, Z., Zhang, M., Pang, X., Zhang, X., & Zhao, L. (2015) · Scientific Reports · doi:10.1038/srep14405 · Cited by 630
Zhang, X., Zhao, Y., Zhang, M., Pang, X., Xu, J., Kang, C., Li, M., Zhang, C., Zhang, Z., Zhang, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042529 · Cited by 615
Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573
Cited by
Sorted by citations
Items 101–144 of 144
Berberine in the treatment of type 2 diabetes - literature review
Mazurek, A., Pawlicki, M., Stachyrak, K., Mika, D., Mazur, B., Turek, K., Lambach, M., Gregułą, A., Kłos, A., & Wilanowska, W. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.67.49000 · Cited by 2
Dietary supplements in therapy to support weight reduction in obese patients [pdf]
Wawrzyniak, N., Skrypnik, K., & Suliburska, J. (2022) · Acta Scientiarum Polonorum Technologia Alimentaria · doi:10.17306/j.afs.2022.1010 · Cited by 2
The anti-aging mechanism of Berberine associated with metabolic control
Guo, X., Xiong, X., Lijun, Z., Zhong, G., & Zhu, X. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823679-6.00020-5 · Cited by 1
Exploring the relationship between berberine and the gut microbiome: A closer look at recent studies
Beyazgül, D., & Aksakal, N. E. (2024) · Anadolu Kliniği Tıp Bilimleri Dergisi · doi:10.21673/anadoluklin.1410170 · Cited by 1
The Use of Phytogenic Substances Against Chronic Stress: Opportunities and Challenges
Basiouni, S., El-Saedi, H., Téllez‐Isaías, G., Eisenreich, W., & Shehata, A. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-70480-2_8 · Cited by 1
Integrative natural health solutions for midlife women
Dahia, V., Shannon, W., Suraev, A. S., Villella, S., Münch, G. W., Chan-Lau, D., & Hunter, D. J. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1629648 · Cited by 1
Health benefits of plant-based nutraceuticals: An updated review
Zahir, A., Nasiru, M. M., Maqsood, S., & Shiam, M. A. H. (2026) · Food and Humanity · doi:10.1016/j.foohum.2026.101144 · Cited by 1
Wang, X., Jacky, H. C. K., Botelho, F. P., Che, Y., Sun, Z., & Xu, W. (2026) · AIMS Animal Science · doi:10.3934/aas.2026004 · Cited by 1
Nanotechnology-driven delivery platforms overcoming the bioavailability challenges of berberine
Chen, X., Cao, W., Meng, X., Zhang, H., Liu, L., & Wang, H. (2026) · Industrial Crops and Products · doi:10.1016/j.indcrop.2026.123564 · Cited by 1
Aphale, P., Gawade, C., Sharma, D. B., Bhonde, R. R., Sanap, A. P., & Kharat, A. H. (2024) · International Journal of High Dilution Research · doi:10.51910/ijhdr.v23icf.1336 · Cited by 1
Bakshi, J., Lather, P., Verma, A., Lather, D., Grewal, S., Dhingra, D., & Kumari, S. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03695-3 · Cited by 1
New therapeutic strategies in the management of obesity-modulated inflammation
Tyszkowski, R., & Mehrzad, R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90960-0.00006-0 · Cited by 1
Obesity and Gut Microbiota: what do we know so far?
Almeida, L. M. D., & Chehter, E. Z. (2023) · Seven Editora eBooks · doi:10.56238/tfisdwv1-037 · Cited by 1
Obesidade e Microbiota Intestinal: o que sabemos até agora?
Almeida, L. M. D., & Chehter, E. Z. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n5-272
Soni, D. K., Naik, N., & Gan, G. (2023) · Journal of Innovations in Pharmaceutical and Biological Sciences · doi:10.56511/jipbs.2023.10401
Gut microbiota and metabolic syndrome: What's new?
Saberi‐Karimian, M., Bana, H. S., Fazeli, M., Tabatabaeizadeh, S., Ferns, G. A., & Ghayour‐Mobarhan, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00050-5
Cheng, C., Sha, W., Xu, B., Zhang, C., Xia, J., & Lei, T. (2024) · Research Square · doi:10.21203/rs.3.rs-3335328/v1
Bakshi, J., Lathar, P., Verma, A., Lather, D., Grewal, S., Dhingra, D., & Kumari, S. (2024) · Research Square · doi:10.21203/rs.3.rs-3928032/v1
A First Magnetic Bio-ionic Liquid for Catalytic Epoxidation of Alkenes
Sharafinezhad, H., Sandaroos, R., Damavandi, S., & Allahresani, A. (2025) · Catalysis Letters · doi:10.1007/s10562-025-05097-3
Lawati, A. A., Alhabsi, A. N., Sabti, A. A., Krishnan, R. S., Alkindi, S., Das, S., & Al-Abri, M. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100387
Alpaslan, A., Uçar, K., Demet, E. D. Ö., Aslan, D. T., Reçber, T., Öztürk, S. C., Gülsün, T., Çelebi̇er, M., & Göktaş, Z. (2025) · Medicina · doi:10.3390/medicina61101738
Tang, J., Chen, H., & Pi, L. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1668886
Nutraceuticals as Dietary Supplements in the Treatment of Childhood Obesity: Myths and Reality
Хавкин, А. И., Nalyotov, A. V., Bystrova, V. I., Sergeev, D. A., Novikova, M. F., Vayman, A. O., & Shrayner, E. V. (2025) · Вопросы современной педиатрии · doi:10.15690/vsp.v24i5.2965
Lee, A., Jung, S.-M., Nam, S.-H., Kim, K.-H., & Han, J.-Y. (2025) · Journal of Korean Medicine for Obesity Research · doi:10.15429/jkomor.2025.25.2.153
Mandlik, D., Mandlik, S., Shrotriya, S. N., Garkal, A., & Rajput, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34003-1.00003-1
Liu, X., Liu, Y.-G., Lv, Y., & Deng, B. (2026) · Current Medical Science · doi:10.1007/s11596-026-00168-x
(2026) · Wiley eBooks · doi:10.1002/9781394381401.ch08
Will Ozempic-style patches help me lose weight? 2 experts explain
Wheate, N., & Chan, W.-J. J. (2026) · doi:10.64628/aa.6hkyfeudp
Isla, M. I., Matteucci, E., Moreno, M. A., Orqueda, M. E., & Zampini, I. C. (2026) · Food & Function · doi:10.1039/d6fo00409a
Muneer, A., Noor, M., Jamshed, S., Shahid, A., Anjum, A., Parveen, F., Rahman, A., & Ali, P. A. (2026) · medtigo Journal of Pharmacology · doi:10.63096/medtigo3061322
Tavana, S., Saeghi, M., Vahdat-Farimani, K., Farhangi, M. J., Bakhtparvar, A., Saberi, M. R., & Chamani, J. (2026) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-026-03494-y
Yang, Y., Zhang, F., Peng, Z., Wu, Y., Li, L., Shen, Z., Ye, Q., Yue, J., & Na, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.029
Zhang, W., Feng, Y., Gao, C., Zhong, L., Wang, W., Xu, M., Zheng, B., Zhang, Y., Wang, S., Yi, S., et al. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02153-9
Francesco, A. D., Munafò, A., Catania, G., Aprile, S. F., Canonico, S., Concerto, C., Rodolico, A., Signorelli, M. S., Leucht, S., & Caraci, F. (2026) · Pharmacopsychiatry · doi:10.1055/a-2869-0635
Berberine and Metabolic Dysfunction‐Associated Steatotic Liver Disease: Hope or Hype?
Nona, R. A., & Kalo, E. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70300
Stephens, D. J., Johnson, E. B., & Johnson, B. J. (2026) · Recent Progress in Nutrition · doi:10.21926/rpn.2603018
Li, W., Guan, S., Li, M., Wang, H., & Chen, F. (2026) · Natural Product Reports · doi:10.1039/d6np00046k
Chi, G., Feng, Y., Jin, S., Li, J., Ren, J., Sun, R., Zhang, W., Xu, X., & Liu, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1804373
Ulusu, N. N. (2026) · Antioxidants · doi:10.3390/antiox15091143 · Cited by 1
Yu, Y., Shan, Y., Chen, Y., Ding, L., & Qian, H. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6c05063
Baek, S., Kang, M. S., Raffa, G. M., Pisano, C., Nuzzi, V., Kowalewski, M., Suwalski, P., & Urbanowicz, T. K. (2026) · Antioxidants · doi:10.3390/antiox15101222
BindingDB (2023) · UC San Diego · doi:10.7270/q28g8qn5
Metadata
- Authors
- Ilyas, Z., Perna, S., Al-thawadi, S., Alalwan, T. A., Riva, A., Petrangolini, G., Gasparri, C., Infantino, V., Peroni, G., & Rondanelli, M.
- Affiliations
- University of Bahrain (BH)
- Indena (Italy) (IT)
- University of Pavia (IT)
- Corresponding author
- Gasparri, Clara
- ORCID
- Venue
- Biomedicine & Pharmacotherapy
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 127
- Pages
- 110137
- ISSN
- 0753-3322 (ISSN-L)
- OpenAlex
- W3017967363
- Cited by
- 143
- References
- 51
- Citations by year
- 2026: 24 · 2025: 33 · 2024: 22 · 2023: 18 · 2022: 21 · 2021: 21 · 2020: 4
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicine & Pharmacotherapy (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- berberine, obesity prevention, weight loss, gut microbiota, α-glucosidase inhibition, adipogenesis, liver X receptor, peroxisome proliferator-activated receptors, SREBP, hepatic gluconeogenesis, phosphoenolpyruvate carboxykinase, AMPK, red yeast rice, lipid lowering, cholesterol absorption, glucose metabolism
- MeSH terms
- Gastrointestinal Microbiome, Berberine, Blood Glucose, Cholesterol, Gluconeogenesis, Humans, Insulin Resistance, Obesity, Weight Loss, Adipocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
